✦ LIBER ✦
A randomized phase III trial of adjuvant endocrine therapy with tamoxifen for one year (TAM1) vs tamoxifen for two years (TAM2) in postmenopausal high risk patients with estrogen receptor positive or estrogen receptor unknown breast cancer. A DBCG study
✍ Scribed by J. Andersen; M. Andersson; K.W. Andersen; P. Dombemowsky; H.T. Mouridsen; C. Rose; M. Kjaer; C. Gadeberg; F.R. Hirsch; A. Moeller
- Book ID
- 117666277
- Publisher
- Elsevier Science
- Year
- 1998
- Tongue
- English
- Weight
- 300 KB
- Volume
- 34
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.